CSIMarket
 


Tscan Therapeutics Inc   (TCRX)
Other Ticker:  
 

Cumulative Tscan Therapeutics Inc 's Long Term Debt to Equity for Trailing Twelve Months Period

TCRX's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

TCRX Long Term Debt to Equity for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth 44.83 % 44.78 % -46.45 % -38.15 % -32.98 %
Y / Y Long Term Debt Growth -0.82 % - - - -
Long Term Debt to Equity for Trailing Twelve Months Period 0.22 0.24 0.21 0.12 0.05
Total Ranking # 900 # 1010 # 953 # 792 # 451
Seq. Equity Growth -11.36 % 144.31 % -21.54 % -14.76 % -11.39 %
Seq. Long Term Debt Growth -2.98 % 0.74 % 0.73 % 0.74 % -


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to long-term debt repayement of -2.98% Tscan Therapeutics Inc decreased Long Term Debt to Equity for Trailing Twelve Months Period in the III. Quarter to 0.22, above Tscan Therapeutics Inc 's average Long Term Debt to Equity for Trailing Twelve Months Period.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 19 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Tscan Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is TCRX selling?
Long Term Debt to Equity TCRX in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 20
Sector # 134
S&P 500 # 749


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.24 0.17 0.05
(Jun 30 2023)   (Sep 30 2022)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Long Term Debt to Equity for Trailing Twelve Months Period
Candel Therapeutics Inc   0.48 
Elevation Oncology inc   0.47 
Biogen Inc   0.47 
Applied Genetic Technologies Corporation  0.39 
Humacyte Inc   0.35 
Poseida Therapeutics Inc   0.35 
Xtant Medical Holdings Inc   0.33 
Qiagen N v   0.33 
Avalon Globocare Corp   0.31 
Instil Bio Inc   0.23 
Scholar Rock Holding Corp  0.22 
Precision Biosciences Inc  0.21 
Tscan Therapeutics Inc   0.20 
Orchard Therapeutics Plc  0.20 
Gritstone Bio Inc   0.20 
Surface Oncology Inc   0.20 
Greenlight Biosciences Holdings Pbc  0.20 
Fusion Pharmaceuticals Inc   0.19 
Aceragen Inc   0.18 
Logicbio Therapeutics Inc   0.17 
Bio techne Corp  0.17 
Omega Therapeutics Inc   0.16 
Inmune Bio Inc   0.13 
Tarsus Pharmaceuticals Inc   0.12 
Finch Therapeutics Group Inc   0.11 
Avrobio Inc   0.08 
Adaptive Biotechnologies Corporation  0.07 
Coeptis Therapeutics Holdings Inc   0.07 
Hillevax Inc   0.06 
Replimune Group Inc   0.04 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com